{"url_path":"/sec/uthr/8-k/2026-06-29/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001104659-26-078865-index.html","accession_number":"0001104659-26-078865","cik":"0001082554","ticker":"UTHR","issuer_name":"UNITED THERAPEUTICS Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001104659-26-078865-index.html","primary_entity_key":"0001082554","primary_entity_name":"UNITED THERAPEUTICS Corp"},"word_count":296,"has_tables":true,"body_markdown":"false\n0001082554\n\n0001082554\n\n2026-06-26\n2026-06-26\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n** **\n\n \n\n****\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15 (d) of\nthe**\n\n**Securities Exchange Act of 1934**\n\n \n\nDate of Report (Date of earliest event reported): \n**June 26, 2026**\n\n \n\n**United Therapeutics Corporation**\n\n(Exact Name of Registrant as Specified in\nits Charter)\n\n \n\n**Delaware**\n \n**000-26301**\n \n**52-1984749**\n\n(State or Other\n \n(Commission\n \n(I.R.S. Employer\n\nJurisdiction of\n \nFile Number)\n \nIdentification Number)\n\nIncorporation)\n \n \n \n \n\n \n\n**1000 Spring Street**\n \n \n\n**Silver Spring, MD**\n \n**20910**\n\n(Address of Principal Executive Offices)\n \n(Zip Code)\n\n \n\nRegistrant’s telephone number, including\narea code: **(301) 608-9292**\n\n \n\nCheck the appropriate box below if the Form 8-K filing\nis intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨Written communications pursuant to Rule 425 under the Securities\nAct (17 CFR 230.425)\n\n \n\n¨Soliciting material pursuant to Rule 14a-12 under the Exchange\nAct (17 CFR 240.14a-12)\n\n \n\n¨Pre-commencement communications pursuant to Rule 14d-2(b) under\nthe Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨Pre-commencement communications pursuant to Rule 13e-4(c) under\nthe Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant\nto Section 12(b) of the Act:\n\n \n\nTitle of each class\n \nTrading symbol(s)\n \nName of each exchange on which\n\nregistered\n\nCommon Stock, par value $0.01 per share\n \nUTHR\n \nNasdaq Global Select Market\n\n \n\nIndicate by check mark whether the registrant is an emerging\ngrowth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of\nthe Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company      ¨\n\n \n\nIf an emerging\ngrowth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with\nany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨"}